. | . | . | . | Gene expression (%) . | . | . | ||
---|---|---|---|---|---|---|---|---|
. | . | . | . | . | Reduced . | . | ||
Gene . | Experimental groups . | Dose/embryo . | n* . | Unchanged . | Weakly . | Strongly . | ||
chordin | Control MO | 16 ng | 67 | 91 | 9 | 0 | ||
chordin | FrdMO | 16 ng | 34 | 26 | 68 | 6 | ||
chordin | DprMO | 8 ng | 30 | 33 | 57 | 10 | ||
chordin | βcatMO | 16 ng | 40 | 5 | 30 | 65 | ||
chordin | FrdMO+DprMO | 8 ng+4 ng | 73 | 3 | 36 | 61 | ||
chordin | FrdMO+DprMO+Frodo | 8 ng+4 ng+1 ng | 55 | 29 | 36 | 35 | ||
chordin | FrdMO+DprMO+βcat | 8 ng+4 ng+10 pg | 65* | 46 | 17 | 17 | ||
Xnr3 | Control MO | 16 ng | 37 | 92 | 8 | 0 | ||
Xnr3 | FrdMO | 16 ng | 38 | 71 | 26 | 3 | ||
Xnr3 | DprMO | 8 ng | 37 | 81 | 16 | 3 | ||
Xnr3 | βcatMO | 16 ng | 40 | 5 | 25 | 70 | ||
Xnr3 | FrdMO+DprMO | 8 ng+4 ng | 48 | 27 | 42 | 31 | ||
Xnr3 | FrdMO+DprMO+Frodo | 8 ng+4 ng+1 ng | 53 | 47 | 38 | 15 | ||
Xnr3 | FrdMO+DprMO+βcat | 8 ng+4 ng+10 pg | 65† | 60 | 9 | 8 | ||
gsc | Control MO | 16 ng | 49 | 88 | 12 | 0 | ||
gsc | FrdMO | 16 ng | 22 | 77 | 23 | 0 | ||
gsc | DprMO | 8 ng | 20 | 85 | 10 | 5 | ||
gsc | βcatMO | 16 ng | 30 | 10 | 20 | 70 | ||
gsc | FrdMO+DprMO | 8 ng+4 ng | 56‡ | 62 | 13 | 7 |
. | . | . | . | Gene expression (%) . | . | . | ||
---|---|---|---|---|---|---|---|---|
. | . | . | . | . | Reduced . | . | ||
Gene . | Experimental groups . | Dose/embryo . | n* . | Unchanged . | Weakly . | Strongly . | ||
chordin | Control MO | 16 ng | 67 | 91 | 9 | 0 | ||
chordin | FrdMO | 16 ng | 34 | 26 | 68 | 6 | ||
chordin | DprMO | 8 ng | 30 | 33 | 57 | 10 | ||
chordin | βcatMO | 16 ng | 40 | 5 | 30 | 65 | ||
chordin | FrdMO+DprMO | 8 ng+4 ng | 73 | 3 | 36 | 61 | ||
chordin | FrdMO+DprMO+Frodo | 8 ng+4 ng+1 ng | 55 | 29 | 36 | 35 | ||
chordin | FrdMO+DprMO+βcat | 8 ng+4 ng+10 pg | 65* | 46 | 17 | 17 | ||
Xnr3 | Control MO | 16 ng | 37 | 92 | 8 | 0 | ||
Xnr3 | FrdMO | 16 ng | 38 | 71 | 26 | 3 | ||
Xnr3 | DprMO | 8 ng | 37 | 81 | 16 | 3 | ||
Xnr3 | βcatMO | 16 ng | 40 | 5 | 25 | 70 | ||
Xnr3 | FrdMO+DprMO | 8 ng+4 ng | 48 | 27 | 42 | 31 | ||
Xnr3 | FrdMO+DprMO+Frodo | 8 ng+4 ng+1 ng | 53 | 47 | 38 | 15 | ||
Xnr3 | FrdMO+DprMO+βcat | 8 ng+4 ng+10 pg | 65† | 60 | 9 | 8 | ||
gsc | Control MO | 16 ng | 49 | 88 | 12 | 0 | ||
gsc | FrdMO | 16 ng | 22 | 77 | 23 | 0 | ||
gsc | DprMO | 8 ng | 20 | 85 | 10 | 5 | ||
gsc | βcatMO | 16 ng | 30 | 10 | 20 | 70 | ||
gsc | FrdMO+DprMO | 8 ng+4 ng | 56‡ | 62 | 13 | 7 |
Four-cell stage embryos were injected in the dorsal equatorial region of two blastomeres with the indicated morpholinos and mRNAs, cultured until stage 10.5 and subjected to whole-mount in situ hybridization with antisense probes for the organizer markers chordin, Xnr3 and gsc.
Data were obtained from three experiments.
Number of embryos scored
Expanded expression of chordin and Xnr3 has been observed in 20% and 23% of injected embryos, respectively
Slightly expanded gsc expression has been observed in 18% of injected embryos